Inhibition of Human Immunodeficiency Virus Type 1 Tat-trans-Activation-Responsive Region Interaction by an Antiviral Quinolone Derivative

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1895-1899

  Richter, Sara ^a   Parolin, Cristina ^a   Gatto, Barbara ^a   Del Vecchio, Claudia ^a   Brocca Cofano, Egidio ^b   Fravolini, Arnaldo ^c   Palù, Giorgio ^a   Palumbo, Manlio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINO 1,4 DIHYDRO 1 METHYL 7 [4 (2 PYRIDYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; 6 AMINOQUINOLONE DERIVATIVE; ANTIVIRUS AGENT; QUINOLONE DERIVATIVE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA SEQUENCE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN NUCLEIC ACID INTERACTION; RNA SEQUENCE; TRANSACTIVATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CIPROFLOXACIN; DNA, VIRAL; GENE PRODUCTS, TAT; HIV LONG TERMINAL REPEAT; HIV-1; MOLECULAR SEQUENCE DATA; MUTATION; PLASMIDS; QUINOLONES; RNA, VIRAL;

EID: 2142753038     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1895-1899.2004     Document Type: Article

References (36)

1. Baba, M., M. Okamoto, M. Kawamura, M. Makino, T. Higashida, T. Takashi, Y. Kimura, T. Ikeuchi, T. Tetsuka, and T. Okamoto. 1998. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53:1097-1103.
2. Baba, M., M. Okamoto, M. Makino, Y. Kimura, T. Ikeuchi, T. Sakaguchi, and T. Okamoto. 1997. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1250-1255.
3. Berkhout, B., and K. T. Jeang. 1989. trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J. Virol. 63:5501-5504.
4. Berkhout, B., R. H. Silverman, and K. T. Jeang. 1989. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59:273-282.
5. Calnan, B. J., B. Tidor, S. Biancalana, D. Hudson, and A. D. Frankel. 1991. Arginine-mediated RNA recognition: the arginine fork. Science 252:1167-1171.
6. Cecchetti, V., C. Parolin, S. Moro, T. Pecere, E. Filipponi, A. Calistri, O. Tabarrini, B. Gatto, M. Palumbo, A. Fravolini, and G. Palu. 2000. 6-Aminoquinolones as new potential anti-HIV agents. J. Med. Chem. 43:3799-3802.
7. Churcher, M. J., C. Lamont, F. Hamy, C. Dingwall, S. M. Green, A. D. Lowe, J. G. Butler, M. J. Gait, and J. Karn. 1993. High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J. Mol. Biol. 230:90-110.
8. Cordingley, M. G., R. L. LaFemina, P. L. Callahan, J. H. Condra, V. V. Sardana, D. J. Graham, T. M. Nguyen, K. LeGrow, L. Gotlib, A. J. Schlabach et al. 1990. Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. Proc. Natl. Acad. Sci. USA 87:8985-8989.
9. Delling, U., S. Roy, M. Sumner-Smith, R. Barnett, L. Reid, C. A. Rosen, and N. Sonenberg. 1991. The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA. Proc. Natl. Acad. Sci. USA 88:6234-6238.
10. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D. Lowe, M. Singh, and M. A. Skinner. 1990. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J. 9:4145-4153.
11. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D. Lowe, M. Singh, M. A. Skinner, and R. Valerio. 1989. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc. Natl. Acad. Sci. USA 86:6925-6929.
12. Feng, S., and E. C. Holland. 1988. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334:165-167.
13. Gelman, M. A., S. Richter, H. Cao, N. Umezawa, S. H. Gellman, and T. M. Rana. 2003. Selective binding of TAR RNA by a Tat-derived beta-peptide. Org. Lett. 5:3563-3565.
14. Hagihara, M., H. Kashiwase, T. Katsube, T. Kimura, T. Komai, K. Momota, T. Ohmine, T. Nishigaki, S. Kimura, and K. Shimada. 1999. Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: a new class of anti-HIV agents. Bioorg. Med. Chem. Lett. 9:3063-3068.
15. Hirsch, M. S., B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, C. Loveday, J. W. Mellors, S. Vella, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279:1984-1991.
16. Huq, I., Y. H. Ping, N. Tamilarasu, and T. M. Rana. 1999. Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides. Biochemistry 38:5172-5177.
17. Huq, I., and T. M. Rana. 1997. Probing the proximity of the core domain of an HIV-1 Tat fragment in a Tat-TAR complex by affinity cleaving. Biochemistry 36:12592-12599.
18. Huq, I., N. Tamilarasu, and T. M. Rana. 1999. Visualizing tertiary folding of RNA and RNA-protein interactions by a tethered iron chelate: analysis of HIV-1 Tat-TAR complex. Nucleic Acids Res. 27:1084-1093.
19. Hwang, S., N. Tamilarasu, K. Kibler, H. Cao, A. Ali, Y. H. Ping, K. T. Jeang, and T. M. Rana. 2003. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278:39092-39103.
20. Hwang, S., N. Tamilarasu, K. Ryan, I. Huq, S. Richter, W. C. Still, and T. M. Rana. 1999. Inhibition of gene expression in human cells through small molecule-RNA interactions. Proc. Natl. Acad. Sci. USA 96:12997-13002.
21. Jakobovits, A., D. H. Smith, E. B. Jakobovits, and D. J. Capon. 1988. A discrete element 3′ of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol. Cell. Biol. 8:2555-2561.
22. Kashiwase, H., K. Momota, T. Ohmine, T. Komai, T. Kimura, T. Katsube, T. Nishigaki, S. Kimura, K. Shimada, and H. Furukawa. 1999. A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication. Chemotherapy 45:48-55.
23. Kesavan, V., N. Tamilarasu, H. Cao, and T. M. Rana. 2002. A new class of RNA-binding oligomers: peptoid amide and ester analogues. Bioconjug. Chem. 13:1171-1175.
24. Ohmine, T., T. Katsube, Y. Tsuzaki, M. Kazui, N. Kobayashi, T. Komai, M. Hagihara, T. Nishigaki, A. Iwamoto, T. Kimura, H. Kashiwase, and M. Yamashita. 2002. Anti-HIV-1 activities and pharmacokinetics of new arylpiperazinyl fluoroquinolones. Bioorg. Med. Chem. Lett. 12:739-742.
25. Okamoto, H., T. P. Cujec, M. Okamoto, B. M. Peterlin, M. Baba, and T. Okamoto. 2000. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 272:402-408.
26. Okamoto, M., T. Okamoto, and M. Baba. 1999. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob. Agents Chemother. 43:492-497.
27. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
28. Parolin, C., B. Gatto, C. Del Vecchio, T. Pecere, E. Tramontano, V. Cecchetti, A. Fravolini, S. Masiero, M. Palumbo, and G. Palù. 2003. New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrob. Agents Chemother. 47:889-896.
29. Simon, R. J., R. S. Kania, R. N. Zuckermann, V. D. Huebner, D. A. Jewell, S. Banville, S. Ng, L. Wang, S. Rosenberg, C. K. Marlowe et al. 1992. Peptoids: a modular approach to drug discovery. Proc. Natl. Acad. Sci. USA 89:9367-9371.
30. 2+-mediated binding of 6-substituted quinolones to DNA: relevance to biological activity. Bioorg. Med. Chem. 6:1555-1561.
31. Sumner-Smith, M., S. Roy, R. Barnett, L. S. Reid, R. Kuperman, U. Delling, and N. Sonenberg. 1991. Critical chemical features in trans-acting-responsive RNA are required for interaction with human immunodeficiency virus type 1 Tat protein. J. Virol. 65:5196-5202.
32. Tamilarasu, N., I. Huq, and T. M. Rana. 1999. High affinity and specific binding of HIV-1 TAR RNA by a Tat-derived oligourea. J. Am. Chem. Soc. 121:1597-1598.
33. Wang, Z., I. Huq, and T. M. Rana. 1999. Proximity of a Tat peptide to the HIV-1 TAR RNA loop region determined by site-specific photo-cross-linking. Bioconjug. Chem. 10:512-519.
34. Wang, Z., and T. M. Rana. 1997. DNA damage-dependent transcriptional arrest and termination of RNA polymerase II elongation complexes in DNA template containing HIV-1 promoter. Proc. Natl. Acad. Sci. USA 94:6688-6693.
35. Weeks, K. M., C. Ampe, S. C. Schultz, T. A. Steitz, and D. M. Crothers. 1990. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 249:1281-1285.
36. Witvrouw, M., D. Daelemans, C. Pannecouque, J. Neyts, G. Andrei, R. Snoeck, A. M. Vandamme, J. Balzarini, J. Desmyter, M. Baba, and E. De Clercq. 1998. Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antivir. Chem. Chemother. 9:403-411.